Business Standard | Cadila to sell cheaper lung cancer drug in India by Dec Business Standard Mycidac-C is for patients suffering from non-small cell lung cancer (NSCLC). Modi said the drug test showed it improved survival possibilities by 28.2 per cent and prolonged survival period by 40 per cent, on an average. The company plans to make the ... Cadila launches novel therapy for lung cancer Cadila launches lung cancer drug at just Rs 40k for a course Cadila Pharma to debut novel lung cancer drug Mycidac-C in India |
